This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pacemakers/ Defibrillators  • Thrombolysis  • Neurology  • Cerebrovascular Disease  • Stroke  • Cardiovascular System  • Arrhythmias  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

JAMA. 2009;301(17):1808.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a Clinical Crossroads article published in October 2003,¹ Daniel E. Singer, MD, discussed the epidemiology of, risk factors for, and treatment considerations for atrial fibrillation (AF). Mrs B, a 60-year-old woman with AF, was concerned about choosing the safest and most effective treatment option for her recently diagnosed AF. Between December 2000 and September 2002, Mrs B experienced palpitations, shortness of breath, and fatigue that increased in frequency and severity and were thought to be related to underlying AF. In September 2002, Mrs B began anticoagulation therapy. Comforted that she was safeguarding herself from stroke, Mrs B wondered about the long-term adverse effects of warfarin and was willing to consider other options. She discussed the possibility of elective cardioversion with her physician but was ambivalent about the adverse effects of subsequent flecainide therapy.

Dr Singer calculated that even without taking warfarin, Mrs B faced a very low risk of . . . [Full Text of this Article]

MRS B

Anna A. Mattson-DiCecca, BA; Eileen Reynolds, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?